NCT05668429View on ClinicalTrials.gov

ADME Study of [14^C]-Ibrexafungerp in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

6

Participants

Timeline

Start Date

December 14, 2022

Primary Completion Date

January 28, 2023

Study Completion Date

January 28, 2023

Conditions

Fungal Disease

Interventions

DRUG

Ibrexafungerp

carbon-14 (\[14\^C\])-Ibrexafungerp

Trial Locations (1)

Unknown

Quotient Sciences Limited, Nottingham

All Listed Sponsors

lead

Scynexis, Inc.

INDUSTRY